Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 20%
Hold 40%
Sell 7%
Strong Sell 0%

Bulls say

Incyte demonstrated strong revenue growth driven by increased demand for Jakafi, which rose 10% year-over-year across all indications, alongside a successful commercial launch of Niktivmo. The company's dermatology product, Opzelura, reported growth ahead of expectations, with revenues reaching $188 million, attributed to rising patient demand for atopic dermatitis and vitiligo treatments. Incyte's raised full-year 2025 guidance to $4.23 billion - $4.32 billion reflects a positive outlook spurred by Jakafi's projecting revenues and contributions from other oncology products, highlighting the potential for continued commercial success.

Bears say

Incyte faces significant downside risks that could negatively impact its financial outlook, particularly concerning its leading drug, Jakafi. Key concerns include the erosion of pricing power for Jakafi, poor performance of the earlier-stage pipeline, and potential clinical or regulatory setbacks related to Jakafi combinations, which could adversely affect future revenue. Additionally, challenges such as competition, reimbursement issues, and safety signals from ongoing launches further exacerbate the company's risks, suggesting a decline in sales growth potential.

Incyte (INCY) has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 15 analysts, Incyte (INCY) has a Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.